CompletedPhase 2NCT00003745
Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas
Studying Alveolar rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Douglas Hawkins, MDSeattle Children's Hospital
- Intervention
- topotecan hydrochloride(drug)
- Enrollment
- 125 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 1999
Study locations (30)
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
- University of South Alabama Medical Center, Mobile, Alabama, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arizona Cancer Center, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Southern California Permanente Medical Group, Downey, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Jonathan Jaques Children's Cancer Center, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
- Children's Hospital Central California, Madera, California, United States
- Children's Hospital of Oakland, Oakland, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003745 on ClinicalTrials.govOther trials for Alveolar rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05304585Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05071209Elimusertib for the Treatment of Relapsed or Refractory Solid TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE3NCT04994132A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk RhabdomyosarcomaChildren's Oncology Group
- RECRUITINGPHASE3NCT06669013Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue SarcomasN.N. Petrov National Medical Research Center of Oncology
- ACTIVE NOT RECRUITINGNCT03296371Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar RhabdomyosarcomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE3NCT02567435Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT00077285Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk RhabdomyosarcomaMemorial Sloan Kettering Cancer Center